- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06767124
Aanvulling van neuro-energie om de cognitie te ondersteunen
Gelijktijdige PET/MR-beeldvorming van hersenglucose en zuurstofmetabolisme om energietekorten te beoordelen die verband houden met de ziekte van Alzheimer en de respons op interventie
It is projected that by 2030, one in every five Americans will be of retirement age, and this demographic shift is expected to result in more people suffering from dementia. A key feature of the brain is its need for a constant supply of glucose and oxygen to meet the high energy costs of mental activity. This study aims to develop clinically practical, noninvasive imaging methods based on combined positron emission tomography and magnetic resonance imaging to assess brain energy in order to better understand how this critical component of brain health is impacted by aging.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
There are now close to six million people in the Unites States living with dementia and this number is only expected to grow as the population continues to age. The current lack of effective treatments for Alzheimer's disease (AD) speaks to the need to better understand the multiple factors that contribute to this complex disease. There is growing evidence that age-related metabolic dysfunction in the brain plays a role in the disease's etiology. This concept has led to treatments aimed at improving brain energy production. Notably, ketogenic dietary supplements have been shown to increase brain ketone metabolism and improve cognitive performance in AD patients. However, the overall benefits to brain metabolism in the AD brain are unknown given the complexity of imaging both oxygen and glucose metabolism in a single session by positron emission tomography (PET). Taking advantage of hybrid PET/MR imaging, this study will combine PET and MRI methods to investigate the effects of a ketogenic supplement on brain oxygen and glucose metabolism in AD patients.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Keith St Lawrence, PhD
- Telefoonnummer: 65737 (519) 646-6100
- E-mail: kstlawr@uwo.ca
Studie Locaties
-
-
Ontario
-
London, Ontario, Canada, N6A 4BQ
- Lawson Research Institute
-
Contact:
- Keith St Lawrence, PhD
- Telefoonnummer: 65737 (519) 646-6100
- E-mail: kstlawr@uwo.ca
-
Hoofdonderzoeker:
- Keith St Lawrence, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria - Alzheimer's Disease Participants: Positive amyloid and tau biomarkers (as noted by PET imaging, cerebrospinal fluid or blood), Mild cognitive impairment or mild-to-moderate dementia, BMI of 18.5-30
Exclusion Criteria: Contraindications to MRI (claustrophobia, metal implants, pacemakers, etc.), Pregnant or breastfeeding women, Neurological disease (healthy participants only), Mental illness, Overt cardio- or neurovascular disease, Recent participation in any procedure(s) involving radioactive agents
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Alzheimer's Disease Patients - Treatment
Patients within the Alzheimer's continuum will be selected based on the National Institute of Aging - Alzheimer's Association Diagnostic Framework and be either classified as having mild cognitive impairment or mild-to-moderate dementia. Participants will undergo two PET/MR sessions in which CMRGlu and CMRO2 will be imaged simultaneously by PET and qBOLD MRI. For validation, CMRO2 will also be imaged by PMROx prior to FDG injection. The study will follow a crossover design in which participants will receive a ketogenic supplement prior to imaging. |
D-Beta-Hydroxybutyrate bonded to R-1,3 Butanediol
Andere namen:
|
|
Placebo-vergelijker: Alzheimer's Disease Patients - Placebo
Patients within the Alzheimer's continuum will be selected based on the National Institute of Aging - Alzheimer's Association Diagnostic Framework and be either classified as having mild cognitive impairment or mild-to-moderate dementia. Participants will undergo two PET/MR sessions in which CMRGlu and CMRO2 will be imaged simultaneously by PET and qBOLD MRI. For validation, CMRO2 will also be imaged by PMROx prior to FDG injection. The study will follow a crossover design in which participants will receive a placebo drink prior to imaging. |
Placebo drink containing flavored water. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cerebral Metabolic Rate of Oxygen (CMRO2)
Tijdsspanne: CMRO2 will be measured in both imaging sessions (placebo and ketosis)
|
Statistical analysis of imaging data sets under placebo and ketosis conditions will be used to investigate increases in regional CMRO2 caused by ketosis. |
CMRO2 will be measured in both imaging sessions (placebo and ketosis)
|
|
Cerebral Metabolic Rate of Glucose (CMRGlu)
Tijdsspanne: CMRGlu will be measured in both imaging session (placebo and ketosis)
|
Statistical analysis of imaging data sets under placebo and ketosis conditions will be used to investigate changes in regional CMRGlu caused by ketosis. Unlike CMRO2, no difference in CMRGlu is expected between the two conditions for Alzheimer's patients. |
CMRGlu will be measured in both imaging session (placebo and ketosis)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cognitive Function
Tijdsspanne: Baseline and 7 Days
|
A psychometrist will assess baseline cognition using the Mini-Mental State Examination, the Montreal Cognitive Assessment, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog). The ADAS-cog will be repeated at the end of the second imaging session to test the potential cognitive benefits of the ketogenic supplement. |
Baseline and 7 Days
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Keith St Lawrence, PhD, Lawson Research Institute
Publicaties en nuttige links
Algemene publicaties
- Panse N, Lafrenaye A, Bergman C, Gerk PM. In vivo pharmacokinetic evaluation of Veech ketone monoester and metabolites in rats after IV (bolus and infusion) and oral administration. Int J Pharm. 2025 Nov 10;684:126130. doi: 10.1016/j.ijpharm.2025.126130. Epub 2025 Sep 6.
- Panse N, Gerk PM. Characterizing the Hepatic Metabolic Pathway of Ketone Ester and Subsequent Metabolites Using Human and Rat Liver Fractions. AAPS J. 2025 Mar 14;27(2):65. doi: 10.1208/s12248-025-01044-7.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 126350
- 1R01NS131235-01A1 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data sets to be shared include imaging data and participant demographics. Data will be made publicly available through the data sharing and archiving platform OpenNeuro.
IPD-tijdsbestek voor delen
Data release will follow a 36-month optional embargo to allow time for publication in a peer-reviewed journal.
IPD-toegangscriteria voor delen
Data submitted to OpenNeuro are first associated with metadata from the BIDS dataset and with submitter-provided metadata, then indexed for searching. Copies of absorbed content -- from each submitted dataset version -- are subsequently assigned persistent digital object identifiers (DOIs).
Datasets will be made publicly available through OpenNeuro with nominal restrictions using multiple open protocols. Prior to being made public, access to a dataset is controlled through strict authentication policies and an isolated storage backend to further guard against unintended access.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .